Publication | Closed Access

Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies

Dose-escalation StudyHematological MalignancyOncologyOral PanobinostatMedicinePhase Ia/iiHematologyPharmacotherapyCancer TreatmentPharmacologyCancer Research